🇺🇸 FDA
Patent

US 9249424

Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

granted A61KA61K38/46A61K38/465

Quick answer

US patent 9249424 (Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases) held by Regents of the University of Minnesota expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/46, A61K38/465, A61K38/47, A61K9/0043